Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety study of ecopipam in Tourette's disorder
2023-503545-67-00Phase 3Authorised
- Sponsor
- Emalex Biosciences
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of ecopipam in Tourette syndrome (TS), sponsored by Emalex Biosciences. Planned start Jul 2023; status: authorised.
02
Drugs
ecopipam
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2023-503545-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503545-67-00.